Psychedelic substances such as LSD, psilocybin and MDMA have increasingly become the focus of science and clinical practice in recent years. The substances are used as part of so-called psychedelic-assisted therapies (PAT), in which psychotherapeutic treatment is combined with the temporary administration of these substances. After research and clinical use largely came to a standstill in the 1970s, modern, controlled studies are now available that provide promising but not yet conclusive data on efficacy and safety.
Autoren
- PD Dr. med. Felix Müller
- Dr. phil. Helena D. Aicher
- Prof. Dr. med. Undine E. Lang
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Malignant oral squamous cell carcinomas (OPSCC/HNSCC)
Innovative Treatment Options
- Acne vulgaris: Topical and Systemic Treatment Options
Spotlight on “Hot Topics”
- Asthma: GINA Guidelines 2026
Focusing Not Only on Treating Symptoms, but Also on Reducing Risk
- Psychiatric Self-Diagnoses
When ADHD and Autism Suddenly Become “Trendy”
- Xerosis cutis in Older Adults
Emollients with humectants such as urea or glycerin: clinical evidence
- Casuistry
Chronic eosinophilic pneumonia in RA
- Case Study: Secondary Pseudohypoaldosteronism
Severe electrolyte imbalances and nonspecific symptoms in an infant
- CKD and High Blood Pressure